: Alzheimer's disease is nowadays the most common cause of dementia. It is a degenerative neurological pathology affecting the brain, progressively leading the patient to a state of total dependence, thus creating a very complex and difficult situation for the family that has to assist him/her. Early diagnosis is a primary objective and constitutes the hope of being able to intervene in the development phase of the disease. : In this paper, a method to automatically detect the presence of Alzheimer's disease, by exploiting deep learning, is proposed. Five different convolutional neural networks are considered: ALEX_NET, VGG16, FAB_CONVNET, STANDARD_CNN and FCNN. The first two networks are state-of-the-art models, while the last three are designed by authors. We classify brain images into one of the following classes: non-demented, very mild demented and mild demented. Moreover, we highlight on the image the areas symptomatic of Alzheimer presence, thus providing a visual explanation behind the model diagnosis. : The experimental analysis, conducted on more than 6000 magnetic resonance images, demonstrated the effectiveness of the proposed neural networks in the comparison with the state-of-the-art models in Alzheimer's disease diagnosis and localization. The best results in terms of metrics are the best with STANDARD_CNN and FCNN with accuracy, precision and recall between 98% and 95%. Excellent results also from a qualitative point of view are obtained with the Grad-CAM for localization and visual explainability. : The analysis of the heatmaps produced by the Grad-CAM algorithm shows that in almost all cases the heatmaps highlight regions such as ventricles and cerebral cortex. Future work will focus on the realization of a network capable of analyzing the three anatomical views simultaneously.

Download full-text PDF

Source
http://dx.doi.org/10.1142/S0129065724500072DOI Listing

Publication Analysis

Top Keywords

alzheimer's disease
16
neural networks
12
visual explainability
8
convolutional neural
8
standard_cnn fcnn
8
state-of-the-art models
8
mild demented
8
alzheimer's
4
disease evaluation
4
evaluation visual
4

Similar Publications

Rationale And Objectives: Alzheimer's disease (AD) is the most common pathogenesis of dementia, and mild cognitive impairment (MCI) is considered as the intermediate stage from normal elderly to AD. Early detection of MCI is an essential step for the timely intervention of AD to slow the progression of this disease. Different form previous studies in the whole-brain spontaneous activities, this research aimed to explore the low-frequency amplitude spectrum activities of patients with MCI within the default mode network (DMN), which has been involved in the process of maintaining normal cognitive function.

View Article and Find Full Text PDF

Abnormal tau phosphorylation is a key mechanism in neurodegenerative diseases. Evidence implicates infectious agents, such as Herpes Simplex Virus 1 (HSV-1), as co-factors in the onset or the progression of neurodegenerative diseases, including Alzheimer's disease. This has led to divergence in the field regarding the contribution of viruses in the etiology of neurodegenerative diseases.

View Article and Find Full Text PDF

Exposure to nano-polystyrene during pregnancy leads to Alzheimer's disease-related pathological changes in adult offspring.

Ecotoxicol Environ Saf

January 2025

Department of Occupational Medicine and Environmental Toxicology, Nantong Key Laboratory of Environmental Toxicology, School of Public Health, Nantong University, Nantong 226019, China. Electronic address:

Nanoplastics are common environmental pollutants. As of now, research has yet to explore how exposure to nanomaterials during gestation might influence the risk of developing Alzheimer's disease (AD) in offspring. Throughout the research, we assessed the AD pathology in adult offspring of mice prenatal 80 nm polystyrene nanoparticles (PS-NPs) exposure.

View Article and Find Full Text PDF

HEBE: A novel chimeric chronokine for ameliorating memory deficits in Alzheimer's disease.

Biomed Pharmacother

January 2025

Institut de Neurociències (INc), Universitat Autònoma Barcelona, Bellaterra 08193, Spain; Vall d'Hebron Institut de Recerca (VHIR), Barcelona 08035, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona 08010, Spain. Electronic address:

Alzheimer's disease (AD) is a prevalent neurodegenerative disorder characterized by amyloid-β and Tau protein depositions, with treatments focusing on single proteins have shown limited success due to the complexity of pathways involved. This study explored the potential of chronokines -proteins that modulate aging-related processes- as an alternative therapeutic approach. Specifically, we focused on a novel pleiotropic chimeric protein named HEBE, combining s-KL, sTREM2 and TIMP2, guided by bioinformatic analyses to ensure the preservation of each protein's conformation, crucial for their functions.

View Article and Find Full Text PDF

Development of multifunctional fluorescence-emitting potential theranostic agents for Alzheimer's disease.

Talanta

January 2025

Pharmaceutical Chemistry Research Laboratory I, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, 221005, India. Electronic address:

The cholinergic deficits and amyloid beta (Aβ) aggregation are the mainstream simultaneously observed pathologies during the progression of Alzheimer's disease (AD). Deposited Aβ plaques are considered to be the primary pathological hallmarks of AD and are contemplated as promising diagnostic biomarker. Herein, a series of novel theranostic agents were designed, synthesised and evaluated against cholinesterase (ChEs) enzymes and detection of Aβ species, which are major targets for development of therapeutics for AD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!